Medical Laboratory Scientist

Labcorp, Charles River and FDA announce research collaboration to advance preclinical methods for evaluating drug abuse potential. Oct 22, 2026, 16:30 ET Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions BURLINGTON, N.C., Oct. 22, 2026 /PRNewswire/ - Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused. The research aims to support safer drug development and more informed regulatory decisions. The collaboration brings together complementary expertise from industry and government. Labcorp will contribute its experience conducting regulatory abuse potential studies, while FDA scientists will conduct data analysis and contribute regulatory science expertise. Together, the organizations aim to advance the science used to evaluate the risk that a medicine could be abused using harmonized behavioral economics methodology to quantify and rank abuse potential. "This research has the potential to improve how abuse-related risks are evaluated and inform decisions throughout drug development and regulatory review," said Brian Caveney, M.D., EVP and president, biopharma laboratory services and chief medical and scientific officer, Labcorp. "Ultimately, this work can support safer therapies, stronger regulatory decision-making and improved protections for patients and communities." Understanding how medicines and emerging substances may be used outside controlled settings is critical to protecting public health and informing regulatory decision-making. The collaboration aims to advance the science used to assess abuse-related risks and generate evidence that may help improve the prediction of real-world use patterns. Labcorp has supported abuse potential evaluation studies since 2009, helping sponsors generate evidence used to inform scheduling, labeling and other regulatory decisions. The company's expertise is complemented by advanced toxicology capabilities that help identify and monitor illicit substances and emerging synthetic drugs, providing insights into evolving drug-use trends and emerging public health threats. Together, these capabilities help researchers understand evolving drug-use trends, identify emerging threats and generate evidence that supports public health and regulatory decision-making. About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements with respect to the benefits of the collaborative study of the potential abuse of medicines. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS." SOURCE Labcorp

Labcorp, Charles River and FDA announce research collaboration to advance preclinical methods for evaluating drug abuse potential. Key Takeaway: Labcorp, the FDA, and Charles River Laboratories announced a collaboration to enhance the evaluation of drug abuse potential. This partnership aims to improve safety in drug development and regulatory decisions by utilizing harmonized behavioral economics methodologies. The initiative seeks to better predict real-world use patterns and protect public health. Price reaction · baseline $329.93 (2026-10-22 close) · hit after-hours · 2 other LH headline(s) in the window, move may be shared day 0 close Market sentiment analysis. Positive FACTORS. * Collaboration aims to improve drug abuse potential evaluation. * Combines expertise from Labcorp, FDA, and Charles River. * Supports safer drug development and regulatory decisions. Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions BURLINGTON, N.C., Oct. 22, 2026 /PRNewswire/ - Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused. The research aims to support safer drug development and more informed regulatory decisions. The collaboration brings together complementary expertise from industry and government. Labcorp will contribute its experience conducting regulatory abuse potential studies, while FDA scientists will conduct data analysis and contribute regulatory science expertise. Together, the organizations aim to advance the science used to evaluate the risk that a medicine could be abused using harmonized behavioral economics methodology to quantify and rank abuse potential. "This research has the potential to improve how abuse-related risks are evaluated and inform decisions throughout drug development and regulatory review," said Brian Caveney, M.D., EVP and president, biopharma laboratory services and chief medical and scientific officer, Labcorp. "Ultimately, this work can support safer therapies, stronger regulatory decision-making and improved protections for patients and communities." Understanding how medicines and emerging substances may be used outside controlled settings is critical to protecting public health and informing regulatory decision-making. The collaboration aims to advance the science used to assess abuse-related risks and generate evidence that may help improve the prediction of real-world use patterns. Labcorp has supported abuse potential evaluation studies since 2009, helping sponsors generate evidence used to inform scheduling, labeling and other regulatory decisions. The company's expertise is complemented by advanced toxicology capabilities that help identify and monitor illicit substances and emerging synthetic drugs, providing insights into evolving drug-use trends and emerging public health threats. Together, these capabilities help researchers understand evolving drug-use trends, identify emerging threats and generate evidence that supports public health and regulatory decision-making. About Labcorp. Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. BiopharmaWatch provide insights and advance science to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com. Cautionary statement regarding forward-looking statements. This press release contains forward-looking statements, including, but not limited to, statements with respect to the benefits of the collaborative study of the potential abuse of medicines. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS." Frequently asked questions. What is the goal of the Labcorp collaboration? The collaboration aims to enhance drug abuse potential evaluation methods. Who are the partners in this research collaboration? Labcorp, the FDA, and Charles River Laboratories are the partners. How will the collaboration improve drug safety? It aims to support safer drug development and informed regulatory decisions. What methodology will be used in the research? Harmonized behavioral economics methodology will be utilized.

Greenberg Traurig advises OPKO Health on $722M+ agreement to sell select BioReference Health assets to Labcorp. Oct 21, 2026, 14:35 ET MIAMI, Oct. 21, 2026 /PRNewswire/ - Global law firm Greenberg Traurig, P.A. advised OPKO Health, Inc., a multinational biopharmaceutical company, on its agreement to sell select assets of its wholly owned subsidiary, BioReference Health, LLC, to Labcorp. The purchase price for the transaction is $722 million in cash at closing, subject to an upward or downward adjustment based on closing business revenues, according to OPKO's press release. The agreement also provides for up to an additional $150 million earnout based on revenue from the 4Kscore(R) Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision. The transaction is subject to regulatory approvals and customary closing conditions. As part of the agreement, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections, and certain operational assets, including more than 80 patient service centers. The Greenberg Traurig deal team was led by Miami Corporate Practice Co-Chair Drew M. Altman and Shareholder Guillaume Le Masson. Corporate Practice Shareholder Robert L. Grossman advised on the deal. Grossman is past chair of the firm's Israel practice, which he helped build and lead for more than 20 years. "We value our longstanding relationship with OPKO and appreciate the trust they placed in us on this transaction," said Corporate Practice Shareholder Robert L. Grossman, who advised on the deal. "This matter reflects the commitment, talent, and hard work of both the OPKO team and the multidisciplinary Greenberg Traurig lawyers who worked together across practices and offices." Other team members included Philadelphia Intellectual Property & Technology Associate Sukhdeep S. Gill; Miami Corporate Associate Ashelin Myus; Washington, D.C., Corporate Associate Macy K. Nix; and Miami Tax Associate Maria Walker. About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com. SOURCE Greenberg Traurig, LLP